Concerto HealthAI to Present AI Model for Predicting Survival of Lung Cancer Patients, with Wide-Ranging Uses for Clinical Development
Summary
Concerto HealthAI announced today that it has developed an AI model predicting survival of lung cancer patients 3-12 months from their last clinical visit. This model will be presented as a research abstract during a poster session at the 2019 American Society of Clinical Oncology’s (ASCO) Annual Meeting in Chicago, on June 1, from 1:15-4:15 p.m. The Gradient Boosting model was built using de-identified structured data from 55,000 lung cancer patients in ASCO’s CancerLinQ Discovery database. “A model that can accurately predict risk of mortality in patients at various time points could help guide clinical development teams to more effectively select attributes of patients for different pre- and post-approval studies to bring needed new therapies forward and enhance the effectiveness of existing therapies respectively,” said Smita Agrawal, Ph.D. and Senior Director of Product Management at Concerto HealthAI and the research abstract’s primary author. Researchers can now determine with a high degree of confidence which patients are expected to survive the next three months and recruit accordingly to ensure a successful clinical trial at a faster pace.